Lavipharm (LAVI) Q4 2024 earnings summary

Executive summary

• Achieved significant sales and EBITDA growth in 2024, with strong increase in net profit year-over-year.

• Expanded strategic partnerships, enriched product portfolio, and strengthened team capabilities.

• Proposed dividend distribution to shareholders, reflecting robust profitability.

Financial highlights

• Consolidated sales from ongoing operations before rebate & clawback rose 12.3% to €61.01 million compared to 2023.

• Gross profit increased 13.2% to €25.08 million year-over-year.

• Adjusted EBITDA from ongoing and discontinued operations grew 14.2% to €10.39 million.

• EBIT reached €5.54 million, up 7% from the previous year.

• Net profit attributable to shareholders surged 380% to €8.98 million, mainly due to deferred tax income from subsidiary liquidation.

Outlook and guidance

• Continued commitment to investing in innovation and human capital for sustainable growth.

• Sales of new OTC antiseptic product expected to begin in the last quarter of the year.